Adolore BioTherapeutics to Present at BioSparkVA Pitch Event

DELRAY BEACH, FL / ACCESSWIRE / September 24, 2024 / Adolore BioTherapeutics, Inc., a biotechnology company developing opioid-free treatments for chronic pain, announced that Roy C. Levitt, MD, the Company's founder and Executive Chairman, will present at BioSparkVA's BioSpark Pitch Event. The event will be held on Thursday, September 26, 2024, in Charlottesville, Virginia.

Adolore is addressing the urgent need for non-opioid analgesic treatments for chronic pain. Dr. Levitt will present Adolore's innovative CA8* chronic pain therapeutic and its technology using disease-free, nontoxic rdHSV vectors. The company has two programs in development: ADB-101 for erythromelalgia and ADB-102 for knee osteoarthritis. Preclinical data supports the progression towards IND filings and first-in-human clinical studies. The rdHSV technology was licensed from the University of Pittsburgh in 2023.

The knee osteoarthritis program is supported by the NIH/NINDS HEAL UH3 Award to the University of Miami, funding pre-clinical development through to a clinical study expected to commence in 2026.